| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
CytomX Therapeutics (NASDAQ:CTMX) reported its Q4 earnings results on Monday, March 11, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
CytomX Therapeutics beat estimated earnings by 133.0%, reporting an EPS of $0.01 versus an estimate of $-0.03.
Revenue was up $25.66 million from the same period last year.
Last quarter the company beat on EPS by $0.23 which was followed by a 2.0% drop in the share price the next day.
Here's a look at CytomX Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.19 | -0.20 | -0.11 | -0.24 |
| EPS Actual | 0.04 | -0.02 | -0.05 | -0.42 |
| Revenue Estimate | 14.14M | 13.88M | 19.59M | 17.85M |
| Revenue Actual | 26.38M | 24.72M | 23.50M | 946K |
To track all earnings releases for CytomX Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CTMX
